Cookies on our website

We use cookies on our website. To learn more about cookies, how we use them on our site and how to change your cookie settings please view our cookie policy. By continuing to use this site without changing your settings you consent to our use of cookies in accordance with our cookie policy.

Read more Close
Skip Ribbon Commands
Skip to main content
Sign In

Introduction

The characterisation and optimisation of the CRISPR (also known as CRISPR/Cas) system for gene editing and other applications is undoubtedly one of the most powerful and ground breaking advances in the history of biotechnology. 

CRISPR technology holds the potential to revolutionise the treatment of disease by enabling DNA to be cut at precise locations, allowing for its accurate and targeted renewal or replacement.  In addition to biomedical applications, there is huge potential for the use of the CRISPR system in agriculture, using genetic modification to introduce positive genetic traits to crops and livestock such as disease resistance, drought tolerance or improved nutritional properties.

But the technology is not without its controversies. At present, CRISPR technology is plagued with a raft of unresolved patent law, licensing, regulatory, policy and moral/ethical issues, which pose a real dilemma for those looking to harness the power of CRISPR and threaten to constrain the vast potential of the technology.

At Allen & Overy, we are committed to helping clients cut through these complexities and to providing insightful analysis of the issues facing current and prospective stakeholders in the CRISPR field.

Use the tabs above to find updates on the latest developments regarding CRISPR, as well as our expert analysis of the key issues.



  • Add comment (optional)